Citations

Clear

44 citation(s) found for "Horowitz, Mary".

Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice
Borogovac, Azra , Efebera, Yvonne A. , DeSalvo, Anna M. , Foley, Amy , Stewart, Valerie , Hamilton, Betty K. , Heuer, Mykala, Molfenter, Todd , Ragon, Brittany Knick , Wall, Sarah , Khera, Nandita , Horowitz, Mary M. , DeZern, Amy E., Bhatt, Neel S , DeSalvo, Anna , Hamilton, Betty K , Molfenter, Todd , Wall, Sarah A , Broglie, Larisa A , Juckett, Mark , Bhatt, Neel S. , Devine, Steven M. , Heuer, Mykala, Plastaras, John Peter , Broglie, Larisa , Dezern, Amy Elizabeth

Mayo Clinic

Blood Advances | June 24, 2025 | Volume: 9 | Issue: 17 | Pages: 4448-4457

10.1182/bloodadvances.2024015405 | PMID 40554428 Get It

Abstract Severe aplastic anemia (SAA) is a rare and life-threatening bone marrow failure disorder. Immunosuppressive therapy (IST) with antithymocyte globulin and cyclosporine has long been a frontline treatment option in SAA; however, its limited durability and risk of long-term complications such as secondary malignancies remain a drawback in this treatment modality. Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative option with significantly improved outcomes over the long term, particularly with HLA-matched related donors. However, the use of alternative donors, such as haploidentical, mismatched, or matched unrelated donors, has previously been limited due to increased transplant-related morbidity, particularly graft-versus-host disease (GVHD). HCTs have therefore been limited to young recipients and those with HLA-matched related donors, creating significant disparity for older adults and those who lack matched donor options. Nevertheless, more recent advances in HCT, such as posttransplant cyclophosphamide for GVHD prophylaxis, have led to improved outcomes of HCT with alternative donors; however, alternative donor HCT remains underused as up-front therapy, in part because of limited multicenter trial data. This review discusses current SAA treatment approaches, including both IST and HCT, and highlights remaining gaps. It also discusses how ongoing clinical trials such as CureAA and TransIT could help address these gaps. Furthermore, we discuss the importance of stakeholder engagement and implementation science in the integration of research-based evidence into clinical practice. Bridging these gaps is necessary for achieving equitable access for patients historically excluded from frontline HCT, including older adults and racially or ethnically diverse populations.
Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704
Sorror, Mohamed L. , Saber, Wael , Logan, Brent R. , Geller, Nancy L. , Bellach, Anna , Kou, Jianqun, McCarty, John M. , Knight, Thomas G. , Runaas, Lyndsey, Johnston, Laura, Nakamura, Ryotaro , Jarrett, Lori, Mishra, Asmita , Uberti, Joseph P., Morris, Lawrence E. , Nadiminti, Kalyan , Olin, Rebecca L. , Sobecks, Ronald , Wall, Sarah , Mattila, Deborah, Protz, Bailey, Horowitz, Mary M. , Geller, Nancy , Knight, Thomas G , Nakamura, Ryotaro , Dahi, Parastoo B , Saultz, Jennifer N , Imus, Philip H , Hogan, William J , Bhatt, Vijaya Raj , Artz, Andrew S , Sorror, Mohamed , Wood, William A. , Walston, Jeremy D , Jarrett, Lori, McCurdy, Shannon , Hogan, William J. , Bhatt, Vijaya Raj , Maakaron, Joseph E. , Devine, Steven M. , Artz, Andrew

Mayo Clinic

Blood Advances | March 18, 2025 | Volume: 9 | Issue: 13 | Pages: 3268-3280

10.1182/bloodadvances.2025015793 | PMID 40101246 Get It

Abstract Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for older adults with hematologic malignancies. Concerns on nonrelapse mortality (NRM) in older adults limit allo-HCT utilization. We executed a prospective, observational study BMT-CTN 1704 (Blood and Marrow Transplant Clinical Trials Network) enrolling allo-HCT recipients aged ≥60 years from 49 centers in the United States. We analyzed associations between 13 measurements of older adult health and NRM within 1 year to construct a comprehensive health assessment risk model (primary-CHARM) using multivariate Fine-Gray model and grouped penalized variable selection. Two machine learning (ML) models (Cox and pseudo-value boosting) were also explored. Models’ performances were compared using area under the curve (AUC), with bootstrap and cross-validation sampling to correct for optimism, decision curve analysis (DCA), calibration, and Brier scores. Among 1105 patients with median age of 67 (range, 60-82) years who received allo-HCT, NRM was 14.4% and overall survival (OS) 71.7% at 1 year. Factors statistically selected for inclusion in primary-CHARM were higher comorbidity burden, lower albumin, higher C-reactive protein, older age, higher weight-loss percentage, lower patient-reported performance score, and cognitive impairment. Primary-CHARM scores were independently associated with higher NRM (hazard ratio [HR], 2.72; P < .0001) and worse OS (HR, 2.09; P < .0001). Bootstrap bias–corrected AUC for primary-CHARM was 0.591. Comparing primary-CHARM with HCT-comorbidity index and 2 ML-CHARM models, calibration, Brier score, and DCA analysis favored primary-CHARM. Primary-CHARM, with mostly simple and readily available parameters, risk stratifies older adults for allo-HCT. Adopting primary-CHARM in practice may promote broader use of HCT by quantifying risk and enhance the design of strategies to improve outcomes. This trial was registered at www.ClinicalTrials.gov as #NCT03992352.
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD –mutated AML
Levis, Mark J. , Hamadani, Mehdi , Logan, Brent R. , Jones, Richard J. , Singh, Anurag K. , Litzow, Mark R. , Papadopoulos, Esperanza B. , Perl, Alexander E. , Soiffer, Robert J. , Üstün, Celalettin , Vasu, Sumithira, Solh, Melhem , Mishra, Asmita , Muffly, Lori , Stelljes, Matthias , Onozawa, Masahiro , Thomson, Kirsty , Nagler, Arnon , Wei, Andrew H. , Marcucci, Guido , Chen, Caroline , Hasabou, Nahla, Rosales, Matt, Gill, Stanley C. , Nuthethi, Rishita, King, Denise , Mendizabal, Adam , Horowitz, Mary M. , Chen, Yi‐Bin , Papadopoulos, Esperanza , Perl, Alexander E , Ustun, Celalettin , Ueda Oshima, Masumi , Uy, Geoffrey , Waller, Edmund K , Muffly, Lori , Kim, Hee-Je , Stelljes, Matthias , Najima, Yuho , Wei, Andrew H , Hill, Jason , Chen, Yi-Bin , Hamadani, Mehdi , Wingard, John R. , Ueda, Masumi , Uy, Geoffrey L. , Waller, Edmund K. , Vasu, Sumithira , Hill, Jason E. , King, Denise, Devine, Steven M.

Mayo Clinic

Blood | January 7, 2025 | Volume: 145 | Issue: 19 | Pages: 2138-2148

10.1182/blood.2024025154 | PMID 39775763 Get It

Abstract BMT CTN (Blood and Marrow Transplant Clinical Trials Network) 1506 (“MORPHO”) was a randomized study of gilteritinib compared with placebo as maintenance therapy after hematopoietic cell transplantation (HCT) for patients with FLT3-ITD–mutated acute myeloid leukemia (AML). A key secondary end point was to determine the impact on survival of before and/or after HCT measurable residual disease (MRD), as determined using a highly sensitive assay for FLT3-ITD mutations. Generally, gilteritinib maintenance therapy was associated with improved relapse-free survival (RFS) for participants with detectable peri-HCT MRD, whereas no benefit was evident for those lacking detectable MRD. We conducted a post hoc analysis of the data and found that the level of MRD detected with this approach correlated remarkably with RFS and relapse risk, and that MRD detectable at any level negatively affected RFS. In the placebo arm, 42.2% of participants with detectable FLT3-ITD MRD relapsed compared with 13.4% of those without detectable MRD. We found that 14.8% of participants had multiple FLT3-ITD clones detected as MRD and had worse survival irrespective of treatment arm. Finally, we examined the kinetics of FLT3-ITD clonal relapse or eradication and found that participants on the placebo arm with detectable MRD relapsed rapidly after HCT, often within a few weeks. MRD-positive participants on the gilteritinib arm relapsed either with FLT3 wild-type clones (assessed by capillary electrophoresis), after cessation of gilteritinib with persistent MRD, or on progression of multiclonal disease. These data demonstrate the potential of FLT3-ITD MRD to guide therapy with gilteritinib for this subtype of AML. This trial was registered at www.clinicaltrials.gov as #NCT02997202.
Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702
Lee, S J, Logan, Brent R. , Horowitz, M., Westervelt, Peter, Pidala, Joseph A. , Dehn, Jason , Hayes‐Lattin, Brandon , Farhadfar, Nosha , Bashey, Asad, Srour, Samer A. , Brunstein, Claudio G. , Symons, Heather J. , Uberti, Joseph P., Pusic, Iskra , Leifer, Eric , He, Naya, Shaw, Bronwen E. , Ciurea, Stefan O. , Horowitz, Mary M. , Hogan, William J. , Grunwald, Michael R. , Devine, Steven M.

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 695-695

10.1182/blood-2024-200833 Get It

Background: A donor search prognosis score based on HLA type and race/ethnicity can classify patients into 3 groups based on the likelihood of finding an HLA-matched (8/8) unrelated donor (MUD): Very Likely (44% of the population), Likely (41%) and Very Unlikely (15%). Previous studies showed that >90% of Very Likely, 26% of Likely and <10% of Very Unlikely patients used a MUD for their hematopoietic cell transplants (HCT), with the rest using other donor sources (mismatched unrelated donor, cord blood, or haploidentical relative). For some patients, prolonged efforts to identify a MUD might be futile and delay HCT, leading to increased morbidity, greater chance for relapse and disease resistance, and worse HCT outcomes. BMT CTN 1702 (NCT03904134) was the first national study to track the entire donor search identification process. Designed as a biologic assignment study, the goal was to estimate and compare overall survival between two arms: patients who are Very Likely to find a MUD versus those who are Very Unlikely to find a MUD. It tested whether provision of a donor search prognosis score to centers could prevent prolonged futile searches for the Very Unlikely group and improve their transplant rates and outcomes, compared to the Very Likely group. Methods: Eligible diagnoses included acute leukemia, myelodysplastic syndromes, lymphoma, acquired aplastic anemia and sickle cell disease. Patients could be consented at any time after diagnosis until an unrelated donor search was started. Consented patients became evaluable only after it was determined that no appropriate HLA-identical siblings were available. The primary endpoint was survival time after the patient was declared evaluable, regardless of whether HCT occurred, and was compared between the Very Unlikely and Very Likely groups. The target enrollment was 1732 evaluable patients. Because this was a biologic assignment trial and not a randomized trial, formal comparisons of overall survival between the Very Likely and Very Unlikely groups were done using a covariate-adjusted Cox proportional hazards model. The following covariates were a priori specified for adjustment in the model, according to the statistical analysis plan: sex, age, Karnofsky Performance Score (KPS), race/ethnicity, disease, disease status, and interval from consent to evaluability. Results: 1751 evaluable patients were enrolled at 47 centers: 44% female, median age 59.4 years (range 0.6-81.3 years), 73% were non-Hispanic White, 10% Hispanic White, 8% Black, 5% Asian/Native Hawaiian/Pacific Islander, 0.5% American Indian/Alaska Native. Among the evaluable patients, 1181 received a HCT, 827 died, and 924 are still alive with or without HCT, with a median of 25 months of follow up (range=6-54 months [mos], inter-quartile range [IQR]=25-34 mos). The distribution was: 958 Very Likely, 517 Less Likely, and 276 Very Unlikely. Individuals in the Very Unlikely group were younger and were less likely to be non-Hispanic White. The unadjusted cumulative incidences of undergoing HCT by 6 mos and 2 years [yrs], in the Very Unlikely group were 51% and 61% vs. 60% and 69% in the Very Likely Group; after adjustment, there was not a significant difference in the likelihood of undergoing HCT (Dehn et al, submitted). There was no difference in median time from evaluability to HCT: 3.4 mos Very Unlikely and 3.3 mos Very Likely. Unadjusted survival rates from the time of evaluability for the Very Unlikely and the Very Likely groups were: 6 mos (85% vs 84%), 1 yr (69% vs. 69%) and 2 yrs (55% vs. 56%). In the multivariate Cox model, there was no significant difference in the risk of death (HR = 1.07 for Very Unlikely vs. Very Likely, 95% confidence interval 0.86-1.33, p=0.56) adjusting for significant clinical covariates: age, KPS, disease status, and time from consent to evaluability were all significantly associated with overall survival. There was no significant center effect and no interaction between donor search prognosis group and clinical covariates. Conclusion: In this large multicenter BMT CTN study, using the donor selection strategy described, there was no difference in adjusted time to HCT or survival for patients Very Likely versus Very Unlikely to find an 8/8 MUD. These results suggest that patients Very Unlikely to identify a MUD should proceed to HCT using the best available alternative donor rather than delaying HCT to try to identify a MUD.
The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704
Saber, Wael , Logan, Brent R., Geller, Nancy L. , Bellach, Anna , Kou, Jianqun, McCarty, John M. , Runaas, Lyndsey, Johnston, Laura, Nakamura, Ryotaro , Mishra, Asmita , Uberti, Joseph P., Morris, Lawrence E. , Nadiminti, Kalyan , Olin, Rebecca L. , Sobecks, Ronald , Wall, Sarah , Mattila, Deborah, Protz, Bailey, Horowitz, M., Sorror, Mohamed L. , Wood, William A. , Knight, Thomas G. , Walston, Jeremy D , Dahi, Parastoo B , Saultz, Jennifer N , McCurdy, Shannon , Imus, Philip H , Hogan, William J. , Bhatt, Vijaya Raj , Maakaron, Joseph E. , Devine, Steven M. , Horowitz, Mary M. , Artz, Andrew

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 685-685

10.1182/blood-2024-194414 Get It

Introduction: The BMT CTN 1704 study developed and validated the CHARM that stratified risk for non-relapse mortality and overall mortality among older adults, performing better than the HCT-CI alone (Artz A et al, Blood. 2023;142:109) and equally to two machine learning models. CHARM assigns a total score for 7 health variables: increasing age, higher HCT-CI scores, lower albumin, higher C-reactive protein, higher percent of weight loss over the preceding year, lower patient-reported performance status scores, and lower cognitive score per Montreal cognitive assessment (MoCA). A CHARM calculator is available at:https://cibmtr.org/CIBMTR/OffNav/DevSandbox/CHARM-Risk-NRM-Calculator No multi-institutional prospective data exist on functional trajectories and morbidity after HCT in older patients. We now report on the association of CHARM to trajectories of secondary morbidity outcomes among allo-HCT survivors of this large, prospective study. Patients and Methods: Allo-HCT candidates, aged ≥60 years (yrs), were enrolled (n=1226) from 49 centers in the US between 2019 - 2021. The primary analysis includes 1105 patients proceeding to allo-HCT on study and secondary endpoints were assessed at day (D) 100, 180 and 365 except MoCA and organ toxicity were restricted to D100 and frailty had inadequate data for D100. A sequential multiple imputation strategy was implemented to impute endpoints for survivors at each time point with missing data. Analyses on multiply imputed datasets were conducted and the results combined using Rubin's rule. Associations between CHARM scores and secondary outcomes were analyzed using a multivariable Cox, Fine-Gray, Generalized Estimating Equations, and logistic regression model for survival, competing risks, continuous, and binary outcomes, respectively, with latter two focused on surviving patients. Models were adjusted for other variables including conditioning intensity, graft-versus-host disease (GVHD) prophylaxis regimen, disease-risk index, donor-recipient gender match, ethnicity, baseline value of the dependent variable, and visit timepoints. Results: Higher CHARM scores were associated with development of serious organ toxicities by D100 (OR: 2.05, [1.52-2.78], p<0.0001) and ≥2 worsening score on the MoCA (odds ratio (OR) 1.55 [1.16-2.1], p=0.003). Among survivors at all timepoints, higher CHARM scores were associated with greater disability by instrumental activities of daily living (IADL) (Slope -0.640 [-0.433-0.846], p<0.001) and worsening Patient-Reported Outcomes Measurement Reporting System (PROMIS) physical function (Slope -0.981 [-0.057 - -1.904], p=0.037), depression (Slope 0.763 [0.042-1.484], p=0.038) and in a lesser magnitude anxiety (Slope 0.659, p=0.076). Among survivors at D180 and D365, higher CHARM scores were associated with worse frailty (Slope 0.193 [0.081-0.305], p<0.001). CHARM scores were not associated with development of acute GVHD grades 2-4 or 3-4 but were associated with post-GVHD increased mortality (HR: 1.61, [1.25-2.08], p=0.0002). Higher CHARM scores are associated with a lower incidence of chronic GVHD (HR: 0.83, p=0.026), likely due to the effect of CHARM on the competing risk of death leaving fewer patients at risk for chronic GVHD. Conclusions: The novel primary CHARM, originally developed to predict risks of NRM, also predicts worse frailty, disability, cognitive decline, and serious organ toxicities; outcomes that are critically important to older recipients of allo-HCT. CHARM therefore informs risks of transplant morbidity, separate from risks of developing acute GVHD. Results further support adopting CHARM in practice to counsel patients, expedite HCT referrals for lower risk CHARM, and design trials for high CHARM score patients.
Trial in Progress: Cureaa - a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207
Mangaonkar, Abhishek A. , Fritz, Amber R. , Bellach, Anna , Malmberg, Craig, Henderson, Lori, DiFronzo, Nancy, Geller, Nancy L. , Ritzau, Nicole M., Sanikommu, Srinivasa Reddy , Tsai, Steven , Horowitz, Mary M. , Arai, Sally , Sharma, Akshay , Kassim, Adetola A , Saldaña, Blachy J. Dávila , Ball, Brian J. , Babushok, Daria V. , Pandey, Manu Raj , Martens, Michael J. , Patel, Sagar S. , Devine, Steven M. , Broglie, Larisa , Dezern, Amy Elizabeth

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 2134.1-2134.1

10.1182/blood-2024-207952 Get It

Background: Immunosuppressive therapy (IST) is considered the standard front-line treatment for acquired severe aplastic anemia (SAA) for pts >40 years. For pts aged <40 years who have a suitable human leukocyte antigen (HLA)-matched sibling donor (MSD), hematopoietic stem cell transplantation (HSCT) is recommended. This recommendation is based on the toxicity associated with alternative donors; haploidentical (HAPLO) and unrelated donor (URD) HSCT for patients who lack a MSD. However, the hematopoietic response after IST is ~ 70-80%, even after augmentation with eltrombopag in the front-line setting, and failure-free survival (FFS, defined as patients alive and in remission without clonal disease more than 10 years after IST) remains < 40%. HSCT is often employed as a second line salvage therapy for those who do not respond to IST or have disease recurrence. However, outcomes after HSCT are often compromised because of IST-related complications such as clonal evolution, development of donor specific antibodies, infectious adverse events and organ dysfunction. In contrast, a successful allogeneic HSCT leads to relatively prompt hematopoietic and immune reconstitution and mitigates the risk of secondary clonal disease. Innovations in recent decades, such as improved graft versus host disease (GVHD) prophylaxis and supportive care, have steadily reduced the morbidity and mortality of adults undergoing HSCT from unrelated or mismatched donors and expanded the donor pool such that almost all pts with SAA have a potential donor available. The use of post-transplant cyclophosphamide (PTCy) is now a well-established approach to facilitate engraftment and mitigate the risk of GVHD. It was successfully used in relapsed/refractory SAA pts using HAPLO donors in the multi-center BMT CTN #1502 trial (NCT02918292). Similar PTCy based approaches have been effective in the upfront setting with HAPLO and URD in small single center studies. Opened in July 2024, the CureAA trial (NCT06517641), seeks to increase donor options for SAA pts who have not yet received IST by using PTCy based GVHD prophylaxis for HSCT using HAPLO or URD. Study Design and Methods: This BMT CTN study (#2207) is a prospective multi-center phase II trial to assess efficacy of HSCT using HAPLO or URD bone marrow with a reduced intensity, thymoglobulin (ATG)-containing preparative regimen and PTCy GVHD prophylaxis in previously untreated SAA pts. This trial has two parallel cohorts for each donor type, HAPLO and URD, with an accrual goal of 30 participants in each cohort. All will receive ATG (0.5mg/kg on day -9 and 2mg/kg on days -8 and -7), cyclophosphamide (14.5mg/kg on days -6 and -5), fludarabine (30mg/m2 on days -6 to -2), 400 cGy total body irradiation (day -1 in a single fraction), a marrow graft (goal >2.5 x 108 nucleated cells per kg of recipient) on day 0 and PTCy (50mg/kg on days +3 and +4). Additionally, participants receive tacrolimus (until day +180) and mycophenolate mofetil days +5-35. The primary objective of the trial is to estimate the GVHD-free failure-free survival (GFFS) rate at 1 year after initiation of conditioning. GFFS is a composite endpoint of survival without grade III-IV acute GVHD, chronic GVHD requiring immunosuppression, or primary or secondary graft failure requiring second definitive therapy within 1 year after initiation of conditioning. Secondary objectives will evaluate patient survival, engraftment, transfusion dependence, cumulative incidence of GVHD and hematologic response. Health related quality of life, healthcare utilization and financial toxicity data will also be collected. These endpoints will allow clinical comparison with current results achieved with upfront IST in other studies. We hypothesize that this HSCT approach will improve survival without significant transplant-associated morbidity by using a low toxicity regimen that reduces rates of GVHD and provides rapid hematologic recovery without graft failure, thereby making HAPLO and URD HSCT a viable option for initial upfront treatment of SAA. The ability to use mismatched donors will also ensure that a HSCT option is more widely available to all racial/ethnic groups. This collaborative study was funded by grants U10HL069294, U24HL138660 to the BMT CTN from the NHLBI/ NCI, along with funding from Sanofi. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD + acute myeloid leukemia
Hamilton, Betty K. , Pandya, Bhavik J. , Ivanescu, Cristina, Elsouda, Dina, Hamadani, Mehdi , Chen, Yi‐Bin , Levis, Mark J. , Ueda, Masumi , Litzow, Mark R. , Soiffer, Robert J. , Üstün, Celalettin , Perl, Alexander E. , Singh, Anurag K. , Geller, Nancy L. , Hasabou, Nahla, Rosales, Matt, Cella, David , Corredoira, Laura, Pestana, Carolina , Horowitz, Mary M. , Logan, Brent R., Ueda Oshima, Masumi , Geller, Nancy , Hamadani, Mehdi

Mayo Clinic

Blood Advances | August 22, 2024 | Volume: 8 | Issue: 19 | Pages: 5091-5099

10.1182/bloodadvances.2024013746 | PMID 39167766 Get It

Abstract The Blood and Marrow Transplant (BMT) Clinical Trials Network conducted a phase 3 randomized trial comparing gilteritinib with placebo after allogeneic hematopoietic cell transplantation (HCT) for FLT3-ITD+ acute myeloid leukemia (AML). The primary analysis demonstrated no statistically significant difference in relapse-free survival (RFS); however, patients with FLT3-ITD measurable residual disease (MRD) peri-HCT had significantly longer RFS with gilteritinib. This analysis investigates the effect of post-HCT gilteritinib vs placebo on health-related quality of life (HRQOL). HRQOL was measured with Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), FACT-Leukemia (FACT-Leu), and EuroQOL-5 Dimensions (EQ-5D-5L) at post-HCT randomization; day 29; months 3, 6, 12, 18, 24; and/or end of therapy. HRQOL and clinically meaningful differences were summarized using descriptive statistics and compared using mixed model repeated measures to evaluate longitudinal change from baseline and stratified Cox model to evaluate time to improvement. HRQOL completion rate was acceptable (>70%) across all time points and measures. There were no differences in HRQOL scores at any time point between cohorts. Clinically meaningful and time to improvement in HRQOL were similar in both arms. Despite higher treatment-emergent adverse effects with gilteritinib, response to the question of being “bothered by side effects of treatment” did not differ between groups. Subgroup analysis of MRD-positive and negative patients demonstrated no differences in HRQOL between arms. For patients with FLT3-ITD+ AML undergoing HCT, gilteritinib maintenance was not associated with any difference in HRQOL or patient-reported impact of side effects. This trial was registered at www.ClinicalTrials.gov as #NCT02997202.
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3
Levis, Mark J. , Hamadani, Mehdi , Logan, Brent R. , Jones, Richard J. , Singh, Anurag K. , Litzow, Mark R. , Wingard, John R. , Papadopoulos, Esperanza B. , Perl, Alexander E. , Soiffer, Robert J. , Üstün, Celalettin , Uy, Geoffrey L. , Vasu, Sumithra, Solh, Melhem , Mishra, Asmita , Muffly, Lori , Mikesch, Jan‐Henrik , Onozawa, Masahiro , Thomson, Kirsty , Nagler, Arnon , Marcucci, Guido , Geller, Nancy L. , Hasabou, Nahla, Delgado, David, Rosales, Matt, Hill, Jason E. , Gill, Stanley C. , Nuthethi, Rishita, King, Denise , Wittsack, Heather, Mendizabal, Adam , Horowitz, Mary M. , Chen, Yi‐Bin , Investigators, on behalf of the BMT-CTN 1506/MORPHO Study, Agura, Ed, Altman, Jessica K. , Anagnostopoulos, Achiles, Aulitzky, Walter E. , Balderman, Sophia , Ballen, Karen K. , Béguin, Yves , Berkahn, Leanne, Bilmon, Ian , Briggs, Adrienne, Brunstein, Claudio G. , Byrne, Michael , Carrum, George, Černý, Jan , Ciceri, Fabio , Colorado, Mercedes , Cook, Rachel J. , Couriel, Daniel R. , Damon, Lloyd E. , Deol, Abhinav , Desbrosses, Yohan, Devine, Steve, Grazia, Carmela Di, Stasi, Antonio Di , Dias, Ajoy , Dorritie, Kathy, Essell, James , Eto, Tetsuya , Forcade, Édouard , Frankfurt, Olga, Fukuda, Takahiro , Fürst, Sabine , Goto, Tatsunori , Hall, Aric C. , Hatta, Shunsuke , Hicheri, Yosr , Horwitz, Mitchell E. , How, Jonathan, Howard, Dianna S. , Hsu, Wei‐Hsun , Huynh, Anne , Irvine, David, Ishikawa, Takayuki , Jamieson, Katarzyna , Wiktor-Jędrzejczak, W , Karakasis, Dimitrios, Kato, Jun , Kekre, Natasha , Khera, Nandita , Klein, A. , Kobbe, Guido , Kornblit, Brian, Lachance, Silvy , Levis, Mark J., Lin, Tung‐Liang , Litzow, Mark, Liu, Ta‐Chih, Martelli, Maurizio , Matsuoka, Ken‐ichi , McCarty, John M. , Mendez, Lourdes , Michelis, Fotios V. , Mikesch, Jan-Henrik, Mineishi, Shin , Moors, Ine , Motyckova, Gabriela, Mueller, Lutz Peter , Muffly, Lori, Nakamae, Hirohisa , Nathan, Sunita , Norkin, Maxim , Ogawa, Yoshiaki, Olesen, G., Onozawa, Masahiro, Paulson, Kristjan, Pemberton, Lucy, Perera, Travis, Perl, Alexander E., Piątkowska‐Jakubas, Beata, Protheroe, Rachel, Ross, Kelly , Santarone, Stella , Sawa, Masashi , Schaar, Dale , Scheid, Christoph, Schriber, Jeffrey, Seropian, Stuart , Shah, Nilay , Shah, Nirav N. , Gil, Jorge Sierra, Sobecks, Ronald , Sprague, Kellie , Spyridonidis, Alexandros , Stelljes, Matthias , Stiff, Patrick J. , Tandra, Anand, Tholouli, Eleni , Thomas, Xavier , Tomlinson, Benjamin , Ustun, Celalettin, Uy, Geoffrey L., Ferreiras, David Valcarcel, Wagner, Eva , Watson, Anne-Marie, Wolschke, Christine, Yamauchi, Takuji , Yeh, Su‐Peng , Logan, Brent , Litzow, Mark R. , Ueda Oshima, Masumi , Uy, Geoffrey , Waller, Edmund K , Solh, Melham M , Mishra, Asmita , Muffly, Lori , Kim, Hee-Je , Najima, Yuho , Onozawa, Masahiro , Nagler, Arnon , Wei, Andrew H , Geller, Nancy , Hill, Jason , Gill, Stanley C , King, Denise , Devine, Steven , Horowitz, Mary , Chen, Yi-Bin , Hamadani, Mehdi , Ueda, Masumi , Waller, Edmund K. , Wei, Andrew H. , Devine, Steven M. , Investigators, on behalf of the BMT-CTN 1506/MORPHO Study, Anagnostopoulos, Achiles, Anand, Sarah , Artz, Andrew , Becker, Michael W. , Berneman, Zwi Nisan , Bhatt, Vijaya Raj , Bonifazi, Francesca , Bruno, Benedetto , Byrne, Jenny , Cabrero, Mónica , Cairoli, Roberto , Cheong, June‐Won , Colorado, Mercedes , Craddock, Charles , Grazia, Carmela Di, Farag, Sherif Shafik , Fujiwara, Shin‐ichiro , Fukushima, Kentaro , Hou, Hsin‐An , Jethava, Yogesh S. , Jiménez, Antonio , Jung, Chul Won , Kanda, Junya , Klein, Andreas, Kota, Vamsi , Leber, Brian F. , Lee, Catherine J , Lee, Je‐Hwan , Levis, Mark J., Litzow, Mark, Martínez, Carmen , Mikesch, Jan-Henrik, Mohty, Mohamad , Mueller, Lutz, Muffly, Lori, Nakano, Nobuaki , Nicholson, Emma , Oluwole, Olalekan O. , Onozawa, Masahiro, Pantin, Jeremy , Perl, Alexander E., Poiré, Xavier , Rambaldi, Alessandro , Ritchie, David , Rubio, Marie‐Thérèse , Sanz, Jaime , Shore, Tsiporah B. , Socié, Gèrard , Stuart, Robert K. , Tanaka, Masatsugu , Tiribelli, Mario , Tsirigotis, Panagiotis D. , Tzachanis, Dimitrios , Uchida, Naoyuki , Ustun, Celalettin, Uy, Geoffrey L., Ferreiras, David Valcarcel, Weisdorf, Daniel J. , Wróbel, Tomasz , Yakoub‐Agha, Ibrahim , Yared, Jean A. , Yoon, Sung‐Soo , Yoshihara, Satoshi

Mayo Clinic

Journal of Clinical Oncology | March 12, 2024 | Volume: 42 | Issue: 15 | Pages: 1766-1775

10.1200/jco.23.02474 | PMID 38471061 Get It

PURPOSE Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of FLT3 ( FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202 ) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit. METHODS Adults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS. RESULTS Three hundred fifty-six participants were randomly assigned post-HCT to receive gilteritinib or placebo. Although RFS was higher in the gilteritinib arm, the difference was not statistically significant (hazard ratio [HR], 0.679 [95% CI, 0.459 to 1.005]; two-sided P = .0518). However, 50.5% of participants had MRD detectable pre- or post-HCT, and, in a prespecified subgroup analysis, gilteritinib was beneficial in this population (HR, 0.515 [95% CI, 0.316 to 0.838]; P = .0065). Those without detectable MRD showed no benefit (HR, 1.213 [95% CI, 0.616 to 2.387]; P = .575). CONCLUSION Although the overall improvement in RFS was not statistically significant, RFS was higher for participants with detectable FLT3-ITD MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.
Post-Hoc Analysis of Measurable Residual Disease from BMT-CTN 1506/Morpho: FLT3-ITD Variant Allele Frequency and Survival Are Highly Correlated
Logan, Brent R. , Jones, Richard J. , Singh, Anurag K. , Litzow, Mark R. , Papadopoulos, Esperanza B. , Perl, Alexander E. , Soiffer, Robert J. , Üstün, Celalettin , Oshima, Masumi Ueda, Vasu, Sumithira, Solh, Melhem , Mishra, Asmita , Muffly, Lori , Stelljes, Matthias , Onozawa, Masahiro , Thomson, Kirsty , Nagler, Arnon , Marcucci, Guido , Hasabou, Nahla, Rosales, Mathew, Gill, Stanley C. , Nuthethi, Rishita, King, Denise , Wittsack, Heather, Mendizabel, Adam, Horowitz, Mary M. , Chen, Yi‐Bin , Muffly, Lori , Levis, Mark J. , Hamadani, Mehdi , Wingard, John R. , Oshima, Masumi Ueda, Uy, Geoffrey L. , Waller, Edmund K. , Vasu, Sumithira , Kim, Hee-Je , Najima, Yuho , Wei, Andrew H. , Rosales, Mathew, Hill, Jason E. , King, Denise, Devine, Steven M.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 973-973

10.1182/blood-2023-177929 Get It

Background: BMT CTN 1506/MORPHO was a randomized study of the FLT3 inhibitor gilteritinib versus placebo as post-transplant (HCT) maintenance therapy for patients (pts) with FLT3-ITD acute myeloid leukemia (AML). Patients with FLT3-ITD AML in first remission underwent HCT and then were randomized, in double-blind fashion, to either gilteritinib or placebo for 24 months. The primary endpoint was relapse-free survival (RFS), and a pre-specified secondary endpoint was the effect of measurable residual disease (MRD) on survival as detected by a highly sensitive assay for FLT3-ITD mutations. In the primary analysis, while RFS was higher for pts randomized to gilteritinib, the difference did not reach the pre-determined threshold for significance (HR: 0.679; 95% CI: 0.459, 1.005; 2-sided p-value: 0.0518). However, in the secondary analysis, the 50.6% of pts who had MRD detectable pre- or post-HCT had significantly higher RFS with gilteritinib (HR of relapse or death=0.515, 95% CI: 0.316, 0.838, p = 0.0065). In this post-hoc analysis, we examined 1) the impact on RFS of different levels of FLT3-ITD variant allele frequency (VAF) pre-randomization (immediately before or after HCT but prior to randomization to gilteritinib or placebo); 2) the impact of the presence of multiple mutations detected as MRD pre-HCT; and 3) the eradication of FLT3-ITD clones detected post-HCT during follow up on gilteritinib or placebo. Methods: First-pull marrow aspirates were collected from pts at two time points pre-randomization (pre-HCT and between 30-90 days post-HCT), as well as at 3, 6, 12, 18, and 24 months post-randomization. For MRD detection (performed at Invivoscribe; San Diego, CA), 700 ng input DNA was amplified by polymerase chain-reaction (PCR) using 25 cycles and primers flanking exons 14 and 15 of FLT3, followed by next-generation sequencing (NGS) analysis of the amplicons. Variant allele frequency (VAF) was calculated as FLT3 mutant reads/total FLT3 reads. For pts with multiple FLT3-ITD mutations, the VAF used in analysis was the sum of the VAFs for each FLT3-ITD variant. The lower limit of blank (LOB) of the assay is estimated to be 1 x 10 -6 VAF. For terminology, VAF > 1 x 10 -6 and < 1 x 10 -5 is referred to as MRD6, VAF > 1 x 10 -5 and < 1 x 10 -4 is MRD5, VAF > 1 x 10 -4 or greater is MRD4, and MRD0 equals no detectable MRD. Results: MRD was evaluated in 350/356 (98.3%) pts pre-HCT and 347/356 (97.5%) pts post-HCT. MRD was detected in 46% of pts pre-HCT and 19.9% prior to randomization, including 4.5% who did not have detectable MRD pre-HCT. The variant allele frequency (VAF) of detectable MRD ranged from a low of 1.09 x 10 -6 to a high of 3.0 x 10 -1. More than a single mutation was detected in 51 pts pre-HCT. Most of these 51 pts had 2 clones, but the total ranged from 2-9. The presence of more than one mutation detected as MRD immediately pre-HCT was associated with worse RFS compared with all other pts (MRD-positive with only one clone and MRD-negative), irrespective of treatment arm (Figure 1A; HR=2.428, 95% CI: 1.555, 3.792, P < 0.001). There was no significant difference in age, mutation length, VAF, or karyotype between pts with more than one mutation and those with single mutations. However, if the VAFs of pts with multiple FLT3-ITD mutations were summed and treated as a single value, then the median VAF for pts with multiple mutations was higher than for those with single mutations (2.14 x 10 -4 vs. 3.12 x 10 -5). The VAF (including the summed VAFs of pts with multiple mutations) at multiple levels correlated very closely with RFS after HCT. To illustrate this quantitative effect of peri-HCT FLT3-ITD VAF on RFS, Kaplan-Meier analysis of pts on the placebo arm grouped by MRD level is displayed in Figure 1B. In the 71 pts with MRD detectable post-HCT, the MRD was eradicated in 69% of pts on gilteritinib versus 44% of pts on placebo. Conclusions Pts with multiple FLT3-ITD mutations have a worse prognosis, which may simply be a reflection of increased disease burden (VAF). The quantity of FLT3-ITD MRD appears to highly correlate with outcome. Gilteritinib appears to augment the effect of HCT, as evidenced by increased eradication of MRD post-HCT. These data illustrate the potential utility of the PCR-NGS FLT3-ITD MRD assay in the management of pts with FLT3-ITD AML.
The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704
Logan, Brent R., Saber, Wael , Geller, Nancy L. , Bellach, Anna , Kou, Jianqun, McCarty, John M. , Runaas, Lyndsey, Johnston, Laura, Nakamura, Ryotaro , Schuler, Tammy A. , Mishra, Asmita , Uberti, Joseph P., Morris, Lawrence E. , Nadiminti, Kalyan , Mattila, Deborah, Protz, Bailey, Horowitz, Mary M. , Artz, Andrew , Wood, William A. , Knight, Thomas G. , Walston, Jeremy D , Dahi, Parastoo B , Saultz, Jennifer N , McCurdy, Shannon , Imus, Philip H , Hogan, William J. , Bhatt, Vijaya Raj , Devine, Steven M. , Sorror, Mohamed L.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 109-109

10.1182/blood-2023-173855 Get It

Introduction: Allogeneic hematopoietic cell transplantation (HCT) remains the only therapy for long-term disease control for many high-risk hematologic malignancies (HM). HCT use in older HM patients (pts) continues to increase. However, concerns of excessive transplant-related morbidity and non-relapse mortality (NRM) limit referrals and broader application of curative intent HCT. The HCT-comorbidity index (HCT-CI) was initially developed to improve risk-stratification of NRM. More recently, geriatric assessment (GA) and biomarkers have emerged as promising additional tools that may refine estimates of these risks. We hypothesized that a combination of health assessments by GA and biomarkers would constitute a robust and valid model, CHARM, for accurate personalized estimation of one-year (1-yr) NRM. Here, we report the results of the largest, first of its kind, prospective study of older recipients of HCT through the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1704 study (NCT03992352). Patients and Methods: Adults aged ≥60 years (yrs) with HM institutionally eligible for HCT were enrolled (n=1226) from 49 centers in the US between 2019 - 2021. Within 21 days of conditioning, 13 prospectively identified older pt.-specific health variables, informed from prior studies, were collected: age, HCT-CI, % of weight loss over the past yr, pt reported Karnofsky performance status, PROMIS physical function scale, instrumental activities of daily living (IADL), number of falls, PROMIS depression scale, number of prescribed medications, 4-meter walk speed, cognition by the Montreal Cognitive Assessment (MoCA), C-reactive protein (CRP) and albumin. The CHARM score to predict NRM within 1 yr was built using a multivariable (MVA) Fine-Gray model, with multiple imputation to handle modest missingness in covariates and grouped penalized variable selection using SCAD to identify variables to retain in the model. Final variables were used as continuous. The model further considered adjustment for conditioning intensity, CMV serostatus, and donor type. Area under the ROC curve (AUC) was calculated to validate the CHARM and compare to HCT-CI alone, with bootstrap sampling to correct for optimism in the within-sample AUC. MVA of overall survival (OS) within 1 yr used the CHARM score and adjusted for other significant variables derived from stepwise regression. Results: The primary analysis included 1105 pts who were confirmed eligible and proceeded to transplant. Median age was 67 (range 60-82) and 32% were ≥ 70 yrs. AML (45%) and MDS (30%) were the most common indications and matched donors the most frequent donor type at 72%. Reduced intensity conditioning with fludarabine (flu)-melphalan (38%) and flu-busulfan (20%) were the most common regimens. Baseline geriatric vulnerabilities among evaluable pts were frequent including slow walk speed (<0.8 meter/second) in 22%, any IADL limitation in 37%, and cognitive impairment (MoCA < 23) in 12%. 1-yr NRM was lower than expected at 14.4% with 1-yr OS of 72%. In the MVA model, albumin, CRP, HCT-CI, and weight loss were independently associated with NRM (Table) and comprised the CHARM. Of note, increasing age did not significantly affect NRM. The CHARM had within sample and bootstrap corrected AUC of 0.641 and 0.607 whereas the HCT-CI alone achieved corresponding AUC values of 0.601 and 0.598. NRM by tertiles is shown in Figure. Each point increase in the CHARM (median -2.2504, range -3.6327 to 0.1381), was associated with a hazard ratio (HR) of 2.83 (95% CI 2.12 - 3.78, p < 0.0001) for NRM. The CHARM also predicted overall mortality within 1-yr with a HR of 2.04 (1.65- 2.53, p <0.0001) per one point increase, independent of the disease risk index, which had a HR of 1.5 (95% CI 1.12 - 1.99, p =0.0059) for high/very high vs low/intermediate categories. Conclusions: We report on the first prospectively established tool, CHARM, to risk-stratify older adult HCT comprised of simple and readily available parameters in transplant and oncology clinics. Adopting CHARM in practice may promote HCT referrals and access for older pts, given low risks of NRM among CHARM lower 2/3 rd tertiles. Identifying high-risk CHARM pts pre-HCT will promote developing novel strategies to reduce NRM. Further analysis of the impacts of the 13 health assessment variables on geriatric morbidity such as disability trajectories is in-process.